These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19890611)

  • 1. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
    Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
    Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaco-economics and decision making in health care. The case of "Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis".
    Tarricone R
    Intern Emerg Med; 2011 Dec; 6(6):581-2. PubMed ID: 21744062
    [No Abstract]   [Full Text] [Related]  

  • 3. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
    Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
    Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
    Sullivan SD; Kwong L; Nutescu E
    Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
    Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
    J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
    Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
    Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
    Wade WE; Spruill WJ; Leslie RB
    Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
    Spruill WJ; Wade WE; Leslie RB
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
    Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
    Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
    Farias-Eisner R; Horblyuk R; Franklin M; Lunacsek OE; Happe LE
    Curr Med Res Opin; 2009 May; 25(5):1081-7. PubMed ID: 19298219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.
    Lundkvist J; Bergqvist D; Jönsson B
    Eur J Health Econ; 2007 Dec; 8(4):313-23. PubMed ID: 17225129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
    Bjorvatn A; Kristiansen F
    Am J Cardiovasc Drugs; 2005; 5(2):121-30. PubMed ID: 15725043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.